ERLEADA Drug Patent Profile

When do Erleada patents expire, and when can generic versions of Erleada launch?

Erleada is a drug marketed by Janssen Biotech and is included in one NDA. There are fourteen patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in ERLEADA is apalutamide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the apalutamide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Erleada

A generic version of ERLEADA was approved as apalutamide by ZYDUS LIFESCIENCES on March 17^th, 2025.

Summary for ERLEADA

US Patents:	14
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	74
Clinical Trials:	22
Patent Applications:	1,912
Drug Prices:	Drug price information for ERLEADA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ERLEADA
What excipients (inactive ingredients) are in ERLEADA?	ERLEADA excipients list
DailyMed Link:	ERLEADA at DailyMed

See drug prices for ERLEADA

Recent Clinical Trials for ERLEADA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Washington	Phase 2
Jonsson Comprehensive Cancer Center	Phase 2
National Cancer Institute (NCI)	Phase 1

See all ERLEADA clinical trials

Paragraph IV (Patent) Challenges for ERLEADA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ERLEADA	Tablets	apalutamide	240 mg	210951	1	2025-03-20
ERLEADA	Tablets	apalutamide	60 mg	210951	5	2022-02-14

US Patents and Regulatory Information for ERLEADA

ERLEADA is protected by eighteen US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Biotech	ERLEADA	apalutamide	TABLET;ORAL	210951-002	Feb 17, 2023		RX	Yes	Yes	8,802,689
Janssen Biotech	ERLEADA	apalutamide	TABLET;ORAL	210951-001	Feb 14, 2018	AB	RX	Yes	No	8,802,689
Janssen Biotech	ERLEADA	apalutamide	TABLET;ORAL	210951-001	Feb 14, 2018	AB	RX	Yes	No	9,388,159		Y	Y

EU/EMA Drug Approvals for ERLEADA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Janssen-Cilag International NV	Erleada	apalutamide	EMEA/H/C/004452Erleada is indicated:in adult men for the treatment of non metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.in adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).	Authorised	no	no	no	2019-01-14

International Patents for ERLEADA

When does loss-of-exclusivity occur for ERLEADA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

France

Guatemala

Hong Kong

Hungary

India

Israel

Japan

Lithuania

Luxembourg

Malaysia

Mexico

Montenegro

Netherlands

New Zealand

Nicaragua

Norway

Peru

Philippines

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Turkey

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ERLEADA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2013323861
Australia	2018206695
Australia	2020244431

Supplementary Protection Certificates for ERLEADA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2368550	300993	Netherlands		PRODUCT NAME: APALUTAMIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/18/1342 20190116
2368550	CA 2019 00029	Denmark		PRODUCT NAME: APALUTAMID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/18/1342 20190116
2368550	2019C/529	Belgium		PRODUCT NAME: APALUTAMIDE OU UN SEL PHARMACOLOGIQUEMENT ADMISSIBLE DE CELLES-CI; AUTHORISATION NUMBER AND DATE: EU/1/18/1342 20190116

ERLEADA Market Dynamics, Sales Growth, Patent Exclusivity, and Financial Trajectory

Last updated: September 17, 2026

ERLEADA, Johnson & Johnson’s oral androgen-receptor inhibitor apalutamide, has become a major prostate-cancer franchise. Global sales rose from roughly $1.1 billion in 2021 to about $2.1 billion in 2023, driven by expanded use in metastatic castration-sensitive prostate cancer and continued adoption in nonmetastatic castration-resistant disease. The principal commercial risks are competition from Xtandi, Nubeqa, and generic abiraterone; future Medicare pricing pressure; and eventual generic entry after core U.S. patent protection expires.

What is ERLEADA and how is it used?

ERLEADA is apalutamide, an oral nonsteroidal androgen-receptor inhibitor marketed by Janssen Pharmaceuticals, a Johnson & Johnson company. It is administered with androgen-deprivation therapy, commonly referred to as ADT.

The U.S. Food and Drug Administration has approved ERLEADA for:

Indication	FDA milestone	Commercial relevance
Nonmetastatic castration-resistant prostate cancer, or nmCRPC	February 2018	Initial launch market
Metastatic castration-sensitive prostate cancer, or mCSPC	July 2019	Expanded addressable population and major sales driver

In nmCRPC, ERLEADA is used in patients with high-risk disease who have no detectable distant metastases but whose prostate-specific antigen levels are rising despite castrate testosterone levels. In mCSPC, it is used with ADT in patients whose cancer has already metastasized but remains hormone-sensitive. The approvals were supported principally by the SPARTAN and TITAN trials (FDA, 2018, 2019).

ERLEADA’s commercial profile depends on long-term treatment duration. Patients generally remain on therapy until disease progression or unacceptable toxicity, supporting recurring revenue rather than a short treatment cycle.

How have ERLEADA sales changed over time?

ERLEADA has delivered rapid sales growth since launch. Johnson & Johnson reports product sales by brand but does not separately disclose U.S. net price, treatment volume, gross-to-net deductions, or profit margin.

Fiscal year	Approximate worldwide ERLEADA sales	Year-over-year trend
2021	$1.1 billion	Strong expansion
2022	$1.6 billion	Approximately 40% growth
2023	$2.1 billion	Approximately 30% growth

Sources: Johnson & Johnson annual reports and earnings disclosures (Johnson & Johnson, 2022, 2023, 2024).

The approximate 2021-2023 sales increase implies a compound annual growth rate of roughly 39%. Growth has been supported by:

• Greater penetration in mCSPC.
• Earlier treatment of advanced prostate cancer.
• Increased use of combination therapy with ADT.
• Expansion outside the United States.
• Physician familiarity with androgen-receptor pathway inhibitors.
• A growing population of patients receiving treatment before chemotherapy.

The sales trajectory is commercially significant because ERLEADA has moved beyond its original nmCRPC niche. The mCSPC label gives Johnson & Johnson access to a larger treatment population, although competition is more intense in that setting.

What is the ERLEADA market size and competitive landscape?

The global market for advanced prostate-cancer androgen-receptor pathway inhibitors includes branded and generic therapies. The main competing products are Xtandi, Nubeqa, and Zytiga or generic abiraterone.

Drug	Active ingredient	Primary companies	Competitive position
ERLEADA	Apalutamide	Johnson & Johnson	Strong in nmCRPC and mCSPC
Xtandi	Enzalutamide	Pfizer and Astellas	Large installed base across prostate-cancer indications
Nubeqa	Darolutamide	Bayer and Orion	Rapid growth, particularly in combination regimens
Zytiga/generic	Abiraterone acetate	Johnson & Johnson originator; multiple generic manufacturers	Lower-cost option with broad use
Orgovyx	Relugolix	Sumitomo Pharma	Oral androgen-deprivation therapy rather than direct AR inhibition

Xtandi has a larger historical commercial base and broad prostate-cancer use. Nubeqa has gained momentum through its use with ADT and docetaxel in metastatic hormone-sensitive disease, as well as in nonmetastatic castration-resistant disease. Abiraterone remains a major price competitor because generic versions are widely available.

ERLEADA competes on clinical efficacy, physician familiarity, treatment sequencing, payer access, and patient tolerability. The choice between branded androgen-receptor inhibitors is often influenced by formulary placement and prior authorization rather than clinical differentiation alone.

How strong is the ERLEADA patent estate?

ERLEADA has a small-molecule patent estate centered on apalutamide composition-of-matter protection, pharmaceutical compositions, and methods of treatment. The core U.S. composition patent is generally identified as U.S. Patent No. 9,266,951, assigned to Aragon Pharmaceuticals and later associated with Johnson & Johnson through corporate acquisition and licensing arrangements.

Patent category	Protection focus	Commercial effect
Composition of matter	Apalutamide and related androgen-receptor modulators	Primary barrier to generic entry
Pharmaceutical composition	Drug formulations and dosage forms	Potential secondary protection
Method of treatment	Use in prostate-cancer populations	Supports litigation and label-based enforcement
Manufacturing and process rights	Production of active ingredient or intermediates	May increase generic development complexity

The core U.S. patent term is generally expected to extend into the early 2030s, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and the precise scope of Orange Book-listed patents. Patent expiration dates must be confirmed against the current FDA Orange Book and USPTO records because the operative date can differ from the nominal 20-year term.

The commercial estate is meaningful but narrower than a biologic patent portfolio. ERLEADA is a small molecule, so generic manufacturers can pursue an abbreviated new drug application rather than a biosimilar application. Manufacturing access and bioequivalence are important, but they do not create the same development barriers seen with complex biologics.

When does ERLEADA lose exclusivity?

ERLEADA’s FDA regulatory exclusivity has expired. The more important remaining barrier is patent protection.

The 2018 approval received five years of new chemical entity exclusivity, while the 2019 supplemental approval expanded the label but did not create a new five-year NCE period. The FDA’s regulatory exclusivity therefore does not prevent ANDA filings today. Generic companies can file paragraph IV certifications against listed patents before patent expiry.

The practical U.S. generic-entry date depends on:

1. The expiration date of the core composition patent.
2. Any patent-term extension or adjustment.
3. Orange Book-listed formulation or method patents.
4. The first paragraph IV filer’s 180-day exclusivity.
5. Patent litigation outcomes.
6. Settlement agreements between Johnson & Johnson and generic applicants.
7. Whether a court grants an injunction or finds the relevant patent valid and infringed.

A reasonable base case is that substantial U.S. generic entry risk begins in the early 2030s, not immediately after regulatory exclusivity ended. Earlier entry could result from a successful paragraph IV challenge or a settlement granting a licensed launch date.

What is the Orange Book status of ERLEADA?

ERLEADA is an FDA-approved small-molecule drug and is listed in the FDA Orange Book under apalutamide products. Orange Book-listed patents can be challenged through ANDA paragraph IV certifications.

The most important Orange Book issues are:

• Whether the composition patent remains listed and enforceable.
• Whether later-listed formulation or method patents materially extend the barrier.
• Whether any listed patent covers the approved ERLEADA dosage form.
• Whether the patents are enforceable against a proposed generic label.
• Whether a generic applicant can use a section viii statement to omit a patented indication.

Method-of-use patents can be commercially weaker than composition patents if a generic product can launch with a restricted label that omits the patented use. A composition patent is generally more difficult to avoid because it covers the active pharmaceutical ingredient itself.

Which companies are challenging ERLEADA patents?

No widely reported U.S. paragraph IV litigation against ERLEADA had produced a major public market event through mid-2024. The absence of a prominent reported challenge does not establish that no ANDA applicant has filed a certification. ANDA filings are often confidential until litigation begins or the FDA publishes relevant approval information.

The likely challenger group consists of large generic manufacturers with experience in oncology products, including Teva, Sandoz, Viatris, Sun Pharma, Dr. Reddy’s Laboratories, and smaller specialty-generic companies. A successful challenger would need to establish invalidity, unenforceability, or noninfringement of the relevant Orange Book patents.

What patent litigation and settlement risks affect ERLEADA?

The highest-value litigation issue is the validity and scope of the core apalutamide patent. Potential defenses include:

• Obviousness based on earlier androgen-receptor antagonists.
• Lack of written description or enablement.
• Noninfringement based on a different formulation or manufacturing route.
• Invalidity of method claims based on prior clinical use or published trial data.
• Patent-term and terminal-disclaimer disputes.

A settlement could allow a generic launch before the nominal patent expiry. The economic value of such an agreement would depend on the launch date, authorized-generic rights, supply terms, and whether multiple generic manufacturers receive licenses.

Johnson & Johnson has used patent litigation and settlement agreements across its broader pharmaceutical portfolio. Any ERLEADA settlement would require review under the Federal Trade Commission’s pharmaceutical patent-settlement framework and could materially change the sales forecast.

Does ERLEADA face biosimilar risk?

ERLEADA does not face biosimilar risk because apalutamide is a chemically synthesized small molecule. It faces conventional generic risk under the Hatch-Waxman framework.

This distinction matters commercially. Generic competition can usually produce faster price erosion than biosimilar competition, particularly when multiple ANDAs launch simultaneously. After several generic entrants, branded small-molecule products can experience substantial volume and price loss.

How does ERLEADA compare with Xtandi and Nubeqa?

Factor	ERLEADA	Xtandi	Nubeqa
Active ingredient	Apalutamide	Enzalutamide	Darolutamide
Core disease areas	nmCRPC, mCSPC	Multiple advanced prostate-cancer settings	nmCRPC, mCSPC
Main owner	Johnson & Johnson	Pfizer and Astellas	Bayer and Orion
Treatment route	Oral	Oral	Oral
Market position	High-growth major franchise	Largest established competitor	Fast-growing challenger
Generic exposure	Early 2030s risk profile	Earlier and indication-dependent exposure	Later-life-cycle product
Key commercial issue	Sustaining growth after mCSPC expansion	Defending a large installed base	Converting clinical momentum into durable share

Nubeqa may be the most important growth competitor because its clinical positioning has expanded in metastatic disease and its tolerability profile can support use in combination regimens. Xtandi remains the most significant direct benchmark for physician familiarity, reimbursement, and global scale.

What is the FDA regulatory outlook for ERLEADA?

The FDA label is established in two major prostate-cancer settings. Future growth is more likely to come from label optimization, treatment sequencing, combination studies, and broader guideline adoption than from a completely new disease area.

Regulatory opportunities include:

• Earlier use in the prostate-cancer treatment pathway.
• Combination regimens with ADT and other systemic therapies.
• Evidence supporting use in high-risk localized or locally advanced disease.
• Biomarker-defined patient selection.
• Data on overall survival and quality of life.

Regulatory risk includes negative or inconclusive trials, safety concerns, treatment discontinuation, and payer resistance to multiple expensive AR pathway inhibitors in the same treatment sequence.

What is the revenue exposure for Johnson & Johnson?

ERLEADA is a material Johnson & Johnson Innovative Medicine product but is smaller than STELARA, DARZALEX, and several other major franchises. At approximately $2.1 billion in 2023 sales, ERLEADA represented a meaningful recurring-revenue asset and an important offset to future losses of exclusivity elsewhere in the portfolio.

Its financial trajectory has three phases:

Period	Expected commercial pattern
2024-2027	Continued growth from mCSPC penetration, international expansion, and treatment duration
2028-2031	Slower growth as market maturity and Nubeqa competition increase
Early 2030s onward	Potential sharp erosion if generic apalutamide launches

The primary forecast variable is not only the patent expiry date. It is the timing of the first generic launch and the number of competitors entering during the first 12 months. A single authorized or licensed generic may produce a gradual decline. Multiple independent generic entrants could cause rapid price compression.

What generic launch scenarios exist for ERLEADA?

Scenario	Likely effect
No challenge until patent expiry	Branded sales continue with gradual pre-expiry erosion
One licensed generic launch	Moderate price and volume pressure
Successful paragraph IV challenge	Earlier-than-expected revenue decline
Multiple generic launches at expiry	Rapid price erosion and share loss
Restricted-label launch	Initial generic use limited to non-patented indications
Authorized generic strategy	Johnson & Johnson retains part of post-expiry economics

The most likely commercial pattern for a successful small-molecule oncology product is a sharp decline after broad generic availability, although specialty distribution, payer contracting, and treatment persistence can moderate the first-year impact.

How geographically broad is ERLEADA protection?

ERLEADA is marketed in the United States and international markets, subject to country-specific approvals, reimbursement decisions, and patent terms. Patent protection is territorial. A U.S. patent expiry does not automatically determine entry timing in Europe, Japan, Canada, or emerging markets.

International revenue is affected by:

• National reimbursement negotiations.
• Reference pricing.
• Local patent-term rules.
• Supplementary protection certificates in Europe.
• Compulsory-license provisions.
• Local manufacturing and import requirements.
• Regional generic approval standards.

The United States is likely to remain the largest single profit pool, but international markets can have earlier generic or price erosion because reimbursement systems often impose lower net prices before patent expiry.

Key Takeaways

• ERLEADA sales increased from approximately $1.1 billion in 2021 to about $2.1 billion in 2023.
• The mCSPC indication is the main growth engine after the original nmCRPC approval.
• Johnson & Johnson faces direct competition from Xtandi and Nubeqa, plus lower-cost generic abiraterone.
• ERLEADA has no biosimilar risk because apalutamide is a small molecule.
• Regulatory exclusivity has expired, but core patent protection is generally expected to extend into the early 2030s.
• The most important legal risk is a paragraph IV challenge to the apalutamide composition patent.
• The commercial decline after generic entry could be rapid if several manufacturers launch at the same time.
• ERLEADA remains a material Johnson & Johnson revenue asset, but its long-term value depends on sustaining mCSPC share and delaying generic competition.

FAQs

What is the active ingredient in ERLEADA?

The active ingredient is apalutamide, an oral androgen-receptor inhibitor used with androgen-deprivation therapy.

Is ERLEADA considered chemotherapy?

No. ERLEADA is hormonal pathway therapy. It blocks androgen-receptor signaling and is used separately from cytotoxic chemotherapy.

Is there a generic version of ERLEADA?

A broadly available FDA-approved generic version was not established through mid-2024. Generic entry depends on ANDA approvals, patent litigation, and any settlement-based launch licenses.

Which drug is more competitive with ERLEADA, Xtandi or Nubeqa?

Xtandi is the larger established competitor, while Nubeqa is the faster-growing strategic threat in several prostate-cancer settings. The competitive outcome depends on indication, payer coverage, treatment sequencing, and physician preference.

Will Medicare negotiation affect ERLEADA?

Direct exposure depends on whether apalutamide is selected for a Medicare drug-price negotiation cycle. Even without direct selection, negotiated prices for competing prostate-cancer therapies can influence payer benchmarks and ERLEADA’s net price.

References

1. U.S. Food and Drug Administration. (2018). FDA approves new treatment for non-metastatic castration-resistant prostate cancer. FDA.

2. U.S. Food and Drug Administration. (2019). FDA approves apalutamide for metastatic castration-sensitive prostate cancer. FDA.

3. Johnson & Johnson. (2022). 2021 annual report. Johnson & Johnson.

4. Johnson & Johnson. (2023). 2022 annual report. Johnson & Johnson.

5. Johnson & Johnson. (2024). 2023 annual report. Johnson & Johnson.

6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

7. U.S. Patent and Trademark Office. (2016). U.S. Patent No. 9,266,951: Androgen receptor modulators. USPTO.

DrugChatter Q&A for ERLEADA

Erleada mechanism of action trial data?
Erleada clinical trial summaries?
Erleada discount?
Us erleada market?